Skip to Content
  • Drug Development

    DNA to Drug?

    A while back, I had a question from a reader about the stories you hear on the news: “New Genetic Discovery Could Lead to Therapy For Disease X”. Just how large is the gap between DNA and a drug? The short answer: mighty spacious. Once in a while, you’re set up for a short cut. Read More
  • Cardiovascular Disease

    More on Merck

    I see that some of the Merck/Vioxx coverage has been along the lines of “Company Finally Heeds Warnings of Unsafe Drug.” Boy, the tort attorneys have to love that sort of thing. It’s true that Merck had some signs that Vioxx could have cardiovascular problems, but there are a lot of drugs, unfortunately, that show… Read More
  • Blog Housekeeping

    Comment Problems

    Something appears to have unraveled in the site’s commenting function; it won’t let anyone post anything. We’ll try to have that fixed soon – in the meantime, I’ll try to think of ways to abuse this newfound freedom from contradiction. Read More
  • Business and Markets

    A Day With All the Bark Left On It

    The talk at every pharmaceutical company today was Merck’s sudden withdrawal of their COX-2 inhibitor Vioxx. Merck has been having an awful time for the last year or two, and this really throws a burning tire on top of the whole heap. They were running a study to see if Vioxx would help prevent the… Read More
  • Drug Prices

    Peter Rost, Oddity

    After mentioning my cheerful outlook on drug reimportation, I should bring up the interesting case of a Pfizer executive, Peter Rost, who also thinks that the drug safety argument is a loser and is willing to say so. (But he’s saying it because he thinks that Canadian reimportation would be a really great idea. This… Read More
  • Drug Prices

    Kicking the Dinosaur’s Tail – Again

    Economist Mark Kleiman, in a clearheaded post on drug reimportation, says: “No doubt, the politicians who are campaigning to permit pharmaceutical arbitrage are demagoging the issue by failing to mention the impact on innovation. But at least the argument they make – that allowing arbitrage would reduce prices to consumers – is more… Read More
  • Business and Markets

    Rank and Yank?

    I don’t usually miss my Monday posts, but time has been short recently. My car, the Rapacious Pharmamobile, has finally given up its last, and I need to replace it quickly so I can drive to work and help rake up the excess profits. In case you’re wondering, the R. Pharmamobile was a 1989 Honda… Read More
  • Business and Markets

    Measure for Mismeasure

    As we start to slide into fall, companies around the industry start to slide into that slough known as Performance Reviews. Depending on your calendar, this can start hitting you any time from now until February or so – it’s particularly joyful when your company changes its system and you have to rank people based… Read More
  • Life in the Drug Labs

    Rational Drug Design

    Not that long ago, my laboratory was doing its usual thing, cranking out the potential Wonder Drugs and sending them downstairs for testing. The results come back in a batch, and we all check to see how everyone’s compounds fared: “Hey, how come that one’s good when the other one isn’t?” “Man, I’m glad I… Read More
  • Blog Housekeeping

    Two Days Off (From This, Anyway)

    No blogging time left this evening, and tomorrow night will be blank as well. I’m giving a talk to the local section of the American Chemical Society, so I’ll be off scarfing up a free meal and enlightening whoever shows up. If you turn down too much free food, the ACS revokes your membership – Read More